Ypsomed -Diabetes Care Business

What Ypsomed -Diabetes Care Business does

Ypsomed (SIX: YPSN) is a Swiss-headquartered, publicly traded medical device company specializing in subcutaneous self-injection systems for pharmaceutical and biotechnology partners. Founded in 1984 as Disetronic and rebranded Ypsomed in 2003 after founder Willy Michel repurchased the pen division from Roche, the company has been repositioned as a pure-play self-injection specialist following the 2024-2025 divestiture of its diabetes care business (mylife Diabetes Care AG) to TecMed AG for up to CHF 420 million.

The company designs, develops, and manufactures pen injectors (YpsoPen, ServoPen, YpsoFlow, UnoPen, FixPen, YpsoDot, LyoTwist), autoinjectors (YpsoMate 1 mL, 2.25 mL, and 5.5 mL; YpsoLoop; VarioJect), and wearable patch injectors (YpsoDose 10 mL), supplemented by digital add-ons including the FDA 510(k)-cleared SmartPilot connectivity module and CliniPilot clinical trial support tool. Its underlying technology relies on modular platform architectures enabling rapid customization from clinical to commercial supply, eco-design principles adopted since 2021, and innovations such as the ClickGuide auditory feedback system and the first circular-design autoinjector (YpsoLoop). R&D is supported by 442 dedicated personnel.

The business model is B2B contract development and manufacturing (CDMO): Ypsomed supplies devices as combination products to pharma partners including Novo Nordisk, Sanofi, Terumo Corporation, Dongbao, and Insulet under long-term supply agreements, with revenue generated through hardware sales, professional CDMO services, and emerging digital health subscriptions. Manufacturing spans Burgdorf and Solothurn (Switzerland), Schwerin (Germany), Changzhou (China, opened June 2025), and Holly Springs, North Carolina (planned for end of 2027), with combined capacity exceeding 500 million devices annually once ongoing expansions are complete.

Name

Ypsomed -Diabetes Care Business

Legal name

Ypsomed AG

Website

https://ypsomed.com

Company type

Public

Founded year

1984

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Ypsomed is a Swiss medical device company that designs and manufactures pen injectors, autoinjectors, and wearable injectors as combination-product platforms for pharmaceutical and biotech partners, operating as a B2B CDMO with global manufacturing in Switzerland, Germany, China, and the United States.

Ownership category

akta.pro rank

Product category

Drug Delivery Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Pen Injectors (Insulin/GLP-1/Other Pens) (HLAHAIAC)

akta.pro secondary industries

Auto-Injectors (Disposable & Reusable) (HLAHAIAB), Wearable Injectors & On-Body Delivery Systems (HLAHAIAE), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

Keywords

• Self-injection systems
• Drug delivery devices
• Autoinjector manufacturing
• Pen injector platforms
• Wearable injectors

Headquarters

HQ city

Burgdorf

HQ country

Switzerland

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. Self-injection Device Manufacturing and Sales: Design, development, and manufacturing of pen injectors, autoinjectors, and wearable injectors sold to pharmaceutical and biotech companies for combination with their drug products. Revenue generated through device sales under long-term supply agreements.
2. Contract Development and Manufacturing Services: CDMO services supporting pharmaceutical partners from clinical development through commercial supply, including regulatory support, testing, quality management, and fill-finish services.
3. Digital Health Solutions: Connected device platforms and digital therapy management tools integrated with injection systems for enhanced patient outcomes and adherence monitoring.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Ypsomed designs, develops, and manufactures self-injection systems including pen injectors, autoinjectors, and wearable injectors as a contract development and manufacturing organization (CDMO) for pharmaceutical and biotechnology companies. The modular platform portfolio supports subcutaneous delivery of GLP-1, biologics, insulin, and other peptide therapies from clinical supply through global commercial launch. Digital health add-ons and clinical trial support services complement the core device offering.

Product overview

Ypsomed offers the most comprehensive and innovative platform portfolio for self-injection systems, comprising pen injectors, autoinjectors, and wearable injectors, supported by digital health solutions and innovation initiatives. The pen injector portfolio includes reusable platforms (YpsoPen, ServoPen, YpsoFlow) and prefilled single-use devices (UnoPen, FixPen, YpsoDot, LyoTwist) for GLP-1, insulin, and peptide therapies. The autoinjector family spans YpsoMate variants (1 mL, 2.25 mL, 5.5 mL), the sustainability-focused YpsoLoop platform, and VarioJect for flexible dosing, with SmartPilot and CliniPilot add-ons enabling digital connectivity and clinical trial support. YpsoDose provides large-volume wearable injection up to 10 mL. Digital health offerings include therapy management platforms and connected device ecosystems, while the Innovation Hub develops reusable mechanical autoinjectors and circularity programs. The Clear to Clinic service enables clinical-ready devices for accelerated trials.

Differentiator

Problem solved

Functional benefit

Brands

• mylife Diabetes Care: Diabetes care products and services including insulin pumps, CGM systems, and related software. Note: Business sold to TecMed AG in 2025.
• YpsoPump
• YpsoMate
• YpsoLoop
• YpsoDose
• SmartPilot
• CliniPilot
• Clear to Clinic

Products and services

• YpsoLoop Sustainable drug delivery autoinjector platform designed for circularity with automated disassembly and efficient recycling. Offers convenience of pre-filled, two-step, single-use device while enabling material recovery. Features ClickGuide technology for use feedback and ergonomic design for patient convenience. Designed for pharmaceutical combination products targeting chronic disease treatments.
• YpsoMate 1 mL two-step prefilled autoinjector for GLP-1 and other therapies. Ergonomic push-on-skin activation for self-injection. Base platform for multiple variants including connected SmartPilot add-on. Designed for pharmaceutical partners requiring combination products for chronic disease medications.
• YpsoMate 2.25 / Pro 2.25 mL two-step prefilled autoinjector for biologics and other therapies. Accommodates larger injection volumes for high-dose drug formulations. Suitable for combination products requiring greater drug volumes per injection.
• YpsoMate 5.5 5.5 mL large-volume prefilled autoinjector for biologics and other high-dose therapies. Supports subcutaneous delivery of larger drug volumes. Recognized with CPHI China 2026 Drug-Device Combination Innovation Award.
• VarioJect Versatile variable dose autoinjector for syringes and cartridges. Accommodates different drug container formats for flexible drug delivery applications. Suitable for pharmaceutical partners requiring versatile dosing across different drug formulations.
• YpsoDose 10 mL prefilled and pre-assembled patch injector (wearable injector) for biologics. Provides subcutaneous delivery of larger volumes for chronic disease treatments requiring sustained or high-dose injections. Suitable for pharmaceutical partners developing large-volume biologic therapies.
• YpsoPen Reusable pen injector for GLP-1, insulin, and other peptide therapies. Variable dose capability for flexible dosing regimens. Designed for pharmaceutical combination products in chronic disease management.
• ServoPen Reusable pen injector for GLP-1, insulin, and other peptide therapies. Established platform with proven reliability. Serves as platform for pharmaceutical combination products across multiple therapeutic areas.
• YpsoFlow Prefilled spring-powered pen injector for peptide therapies. Provides consistent dose delivery with mechanical spring drive. Designed for pharmaceutical combination products in chronic disease management.
• FixPen Prefilled fixed-dose pen injector for peptide therapies. Simple operation with predetermined dose delivery. Designed for pharmaceutical combination products where fixed dosing is required.
• UnoPen Prefilled variable dose pen for GLP-1 and peptide therapies. Single-use device with variable dosing flexibility. Designed for pharmaceutical combination products requiring prefilled variable-dose delivery.
• YpsoDot Next-generation pull-push pen injector. Innovative mechanism for subcutaneous drug delivery. Designed for pharmaceutical combination products in chronic disease management.
• LyoTwist Reconstitution auto-injector for lyophilized (freeze-dried) drugs. Enables self-mixing and injection of drugs that require reconstitution before administration. Designed for pharmaceutical combination products requiring dual-chamber reconstitution.
• Clear to Clinic Service offering enabling clinic-ready YpsoMate 1 mL and YpsoMate 2.25 mL autoinjectors for clinical trials. Accelerates trial readiness and reduces study risk through pre-validated devices. Targeted at pharmaceutical trial sponsors and CROs conducting clinical studies requiring injection device support.

Quantifiable outcome

• 20% revenue growth in core Delivery Systems business
• +4 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability3 records

Feature7 records

Partnerships

Six partnerships are on record, tiered core and important.

• Stevanato GroupcoreTechnology or Integration · 23 June 2026Collaboration on integration and compatibility of EZ-fill prefilled syringes (PFS) into the YpsoMate platform. Expanding capacity for high-viscosity formulations. This partnership advances high-dose drug delivery solutions for pharmaceutical customers.
• S3 Connected HealthcoreTechnology or Integration · 1 January 2023Partnership to expand digital health offering for pharmaceutical companies to support patients with acute and chronic diseases. Enables integrated device and digital health solutions without long development times.
• CamDiab LtdcoreTechnology or Integration · 1 January 2022Cooperation for CamAPS FX app controlling insulin pump using adaptive hybrid closed-loop system. mylife YpsoPump users benefit from self-learning algorithm running on smartphone for better glucose control.
• Sidekick HealthimportantStrategic or Co-development Partner · 1 January 2022Combination of Ypsomed injection systems with Sidekick's digital health, behavioral economics and gamification expertise. Offers motivating and personalized patient experience for chronic disease management.
• DexcomcoreTechnology or Integration · 1 January 2020Partnership with world's leading CGM provider to establish hybrid closed-loop system. Glucose data from CGM sensor integrated into mylife app as first step toward automated insulin dosing.
• Terumo CorporationcoreStrategic or Co-development Partner · 1 January 2018Collaboration on Hulio project resulting in first commercial YpsoMate market entry. Terumo developed specially designed PLAJEX syringe for administering adalimumab drug.

Scale indicators21 records

Recent moves12 records

Expansion highlights7 records

Direct peers

• West Pharmaceutical Services: Global leader in primary packaging and delivery systems for injectable drugs, including elastomer components and self-injection platforms. Directly comparable as a pharma CDMO serving large biologics and insulin franchises with combination product expertise.
• SHL Medical: Pure-play autoinjector manufacturer with strong position in 1 mL and 2.25 mL devices, serving major pharma partners. Most direct head-to-head competitor in the prefilled autoinjector platform category.
• Phillips-Medisize (Molex): Drug delivery device CDMO offering autoinjector, inhaler, and connected device manufacturing services to pharma. Direct competitor for combination product contract development and manufacturing work.
• Stevanato Group: Italian drug containment and delivery solutions provider offering EZ-fill syringes, vials, and device platforms. Recently partnered with Ypsomed on EZ-fill PFS integration into YpsoMate — competes in glass primary packaging while collaborating on combination products.
• Owen Mumford: UK-based privately held manufacturer of autoinjectors, pen injectors, and lancets for pharma partners. Similar platform-based business model focused on self-injection devices for biologics and chronic disease therapies.
• Gerresheimer: European pharmaceutical packaging and drug delivery device manufacturer with autoinjector and pen injector offerings. Comparable as a pharma-facing device platform company with global manufacturing footprint.
• Dätwyler (Haselmeier): Swiss parent company of Haselmeier, which develops autoinjector platforms (D-Flex, i-Pen) for pharma partners. Direct competitor in prefilled autoinjector systems with overlapping European customer base.

Broad incumbents

• Becton, Dickinson and Company: Massive diversified medical technology company with a Pharmaceutical Systems segment supplying prefilled syringes, autoinjectors (BD Physioject), and drug delivery devices. Overlaps in combination product offerings but operates at much broader portfolio scale.
• Catalent (Novo Holdings): Global CDMO with biologics fill-finish and drug delivery capabilities, recently acquired by Novo Holdings. Comparable as a pharma CDMO partner, particularly relevant given Novo Nordisk's ownership and overlap with Ypsomed's anchor customer relationships.

Emerging players

• Enable Injections: US-based developer of large-volume wearable injectors (enFuse) for subcutaneous delivery of biologics. Overlaps with YpsoDose in the wearable injector category but at earlier commercialization stage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ypsomed-ag

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ypsomed -Diabetes Care Business